{"id":4422586,"date":"2025-01-12T06:41:47","date_gmt":"2025-01-12T12:41:47","guid":{"rendered":"https:\/\/myendoconsult.com\/learn\/topics\/lipid-lowering-therapy\/"},"modified":"2025-01-12T07:01:41","modified_gmt":"2025-01-12T13:01:41","slug":"lipid-lowering-therapy","status":"publish","type":"oen_topic","link":"https:\/\/myendoconsult.com\/learn\/topics\/lipid-lowering-therapy\/","title":{"rendered":"Lipid Lowering Therapy"},"content":{"rendered":"\n<h2 class=\"wp-block-heading\">OVERVIEW OF LIPID-LOWERING AGENTS<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Main Classes<\/strong>:\n<ol class=\"wp-block-list\">\n<li><strong>Cholesterol absorption inhibitors<\/strong><\/li>\n\n\n\n<li><strong>3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase inhibitors (statins)<\/strong><\/li>\n\n\n\n<li><strong>Bile acid sequestrants<\/strong><\/li>\n\n\n\n<li><strong>Nicotinic acid<\/strong><\/li>\n\n\n\n<li><strong>Fibric acid derivatives<\/strong><\/li>\n\n\n\n<li><strong>Fish oil (omega-3 fatty acids)<\/strong><\/li>\n<\/ol>\n<\/li>\n\n\n\n<li><strong>Key Overall Benefits<\/strong>:\n<ul class=\"wp-block-list\">\n<li>Lowering harmful lipids (<a href=\"https:\/\/myendoconsult.com\/learn\/what-is-ldl-cholesterol\/\" data-wpil-monitor-id=\"293\">LDL cholesterol<\/a>, triglycerides)<\/li>\n\n\n\n<li>Potentially <strong>reducing <a href=\"https:\/\/myendoconsult.com\/learn\/topics\/atherosclerosis\/\" data-wpil-monitor-id=\"292\">atherosclerosis<\/a><\/strong> and stabilizing plaques<\/li>\n\n\n\n<li>Improving endothelial function<\/li>\n\n\n\n<li>Decreasing thrombogenesis<\/li>\n<\/ul>\n<\/li>\n<\/ul>\n\n\n\n<hr class=\"wp-block-separator has-alpha-channel-opacity\"\/>\n\n\n\n<h3 class=\"wp-block-heading\">1. CHOLESTEROL ABSORPTION INHIBITORS<\/h3>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Example<\/strong>: <strong>Ezetimibe<\/strong><\/li>\n\n\n\n<li><strong>Mechanism<\/strong>:\n<ul class=\"wp-block-list\">\n<li>Blocks cholesterol absorption at the brush border of the intestine<\/li>\n\n\n\n<li>Targets <strong>Niemann-Pick C1\u2013like 1<\/strong> (NPC1L1) proteins<\/li>\n<\/ul>\n<\/li>\n\n\n\n<li><strong>Effect<\/strong>:\n<ul class=\"wp-block-list\">\n<li>Lowers serum low-density lipoprotein (<strong>LDL<\/strong>) cholesterol by ~17%<\/li>\n\n\n\n<li>Has additive LDL-lowering effects when combined with statins<\/li>\n<\/ul>\n<\/li>\n\n\n\n<li><strong>Selectivity<\/strong>:\n<ul class=\"wp-block-list\">\n<li>Does <strong>not<\/strong> affect absorption of triglycerides or fat-soluble vitamins<\/li>\n<\/ul>\n<\/li>\n<\/ul>\n\n\n\n<hr class=\"wp-block-separator has-alpha-channel-opacity\"\/>\n\n\n\n<h3 class=\"wp-block-heading\">2. HMG-CoA REDUCTASE INHIBITORS (STATINS)<\/h3>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Mechanism<\/strong>:\n<ul class=\"wp-block-list\">\n<li>Competitive inhibitors of the enzyme <strong>HMG-CoA reductase<\/strong>, the rate-limiting step in cholesterol biosynthesis<\/li>\n\n\n\n<li>Decreased intracellular cholesterol \u2192 upregulation of <strong>LDL receptor<\/strong> turnover<\/li>\n<\/ul>\n<\/li>\n\n\n\n<li><strong>Lipid Effects<\/strong>:\n<ul class=\"wp-block-list\">\n<li>Lowers serum LDL cholesterol by <strong>30\u201360%<\/strong><\/li>\n\n\n\n<li>Decreases small dense LDL (more atherogenic)<\/li>\n\n\n\n<li>Typically lowers triglycerides by <strong>20\u201340%<\/strong><\/li>\n\n\n\n<li>Increases HDL cholesterol by <strong>5\u201310%<\/strong><\/li>\n<\/ul>\n<\/li>\n\n\n\n<li><strong>Examples<\/strong>:\n<ul class=\"wp-block-list\">\n<li><strong>Lovastatin, Simvastatin, Pravastatin, Fluvastatin, Atorvastatin, Pitavastatin, Rosuvastatin<\/strong><\/li>\n<\/ul>\n<\/li>\n<\/ul>\n\n\n\n<hr class=\"wp-block-separator has-alpha-channel-opacity\"\/>\n\n\n\n<h3 class=\"wp-block-heading\">3. BILE ACID SEQUESTRANTS<\/h3>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Examples<\/strong>: <strong>Cholestyramine, Colestipol, Colesevelam<\/strong><\/li>\n\n\n\n<li><strong>Mechanism<\/strong>:\n<ul class=\"wp-block-list\">\n<li>Bind bile acids in the intestine \u2192 interrupt normal (90%) reabsorption<\/li>\n\n\n\n<li>Depleted bile acids = <strong>increased LDL receptor<\/strong> expression in hepatocytes<\/li>\n<\/ul>\n<\/li>\n\n\n\n<li><strong>Effects<\/strong>:\n<ul class=\"wp-block-list\">\n<li>Reduce serum LDL cholesterol by <strong>10\u201324%<\/strong><\/li>\n\n\n\n<li>Additive effects with statins (can further lower LDL)<\/li>\n<\/ul>\n<\/li>\n\n\n\n<li><strong>Specific Consideration<\/strong>:\n<ul class=\"wp-block-list\">\n<li>May affect absorption of other drugs or nutrients if taken simultaneously<\/li>\n<\/ul>\n<\/li>\n<\/ul>\n\n\n\n<hr class=\"wp-block-separator has-alpha-channel-opacity\"\/>\n\n\n\n<h3 class=\"wp-block-heading\">4. NICOTINIC ACID (NIACIN)<\/h3>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Mechanism<\/strong>:\n<ul class=\"wp-block-list\">\n<li>Decreases hepatic production of <strong>very low-density lipoproteins (VLDL)<\/strong><\/li>\n\n\n\n<li>Reduces lipolysis to LDL<\/li>\n\n\n\n<li>Enhances <strong>HDL<\/strong> cholesterol by inhibiting its clearance<\/li>\n<\/ul>\n<\/li>\n\n\n\n<li><strong>Effects<\/strong>:\n<ul class=\"wp-block-list\">\n<li>Increases HDL by up to <strong>35%<\/strong><\/li>\n\n\n\n<li>Lowers LDL and triglycerides to varying degrees<\/li>\n<\/ul>\n<\/li>\n\n\n\n<li><strong>Formulations<\/strong>:\n<ul class=\"wp-block-list\">\n<li>Immediate-release (crystalline)<\/li>\n\n\n\n<li>Sustained-release<\/li>\n<\/ul>\n<\/li>\n\n\n\n<li><strong>Clinical Note<\/strong>:\n<ul class=\"wp-block-list\">\n<li>Common side effect: Flushing (can be mitigated with aspirin pre-treatment)<\/li>\n<\/ul>\n<\/li>\n<\/ul>\n\n\n\n<hr class=\"wp-block-separator has-alpha-channel-opacity\"\/>\n\n\n\n<h3 class=\"wp-block-heading\">5. FIBRIC ACID DERIVATIVES<\/h3>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Examples<\/strong>: <strong>Gemfibrozil, Fenofibrate<\/strong><\/li>\n\n\n\n<li><strong>Mechanism<\/strong>:\n<ul class=\"wp-block-list\">\n<li>Activate <strong>peroxisome proliferator\u2013activated receptor-\u03b1 (PPAR-\u03b1)<\/strong><\/li>\n\n\n\n<li>Decrease hepatic VLDL secretion<\/li>\n\n\n\n<li>Stimulate <strong>lipoprotein lipase (LPL)<\/strong> activity<\/li>\n\n\n\n<li>Downregulate <strong>apolipoprotein (apo) CIII<\/strong> expression<\/li>\n<\/ul>\n<\/li>\n\n\n\n<li><strong>Effects<\/strong>:\n<ul class=\"wp-block-list\">\n<li>Lower triglycerides by <strong>35\u201350%<\/strong><\/li>\n\n\n\n<li>Increase HDL by <strong>15\u201325%<\/strong><\/li>\n\n\n\n<li>May modestly lower LDL or have variable LDL effects depending on the baseline lipid profile<\/li>\n<\/ul>\n<\/li>\n<\/ul>\n\n\n\n<hr class=\"wp-block-separator has-alpha-channel-opacity\"\/>\n\n\n\n<h3 class=\"wp-block-heading\">6. FISH OIL (OMEGA-3 FATTY ACIDS)<\/h3>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Active Components<\/strong>:\n<ul class=\"wp-block-list\">\n<li><strong>Eicosapentaenoic acid (EPA, 20:5n-3)<\/strong><\/li>\n\n\n\n<li><strong>Docosahexaenoic acid (DHA, 22:6n-3)<\/strong><\/li>\n<\/ul>\n<\/li>\n\n\n\n<li><strong>Mechanism<\/strong>:\n<ul class=\"wp-block-list\">\n<li>Exact action not fully clarified<\/li>\n\n\n\n<li>Decrease hepatic secretion of triglycerides (likely by reducing VLDL production)<\/li>\n<\/ul>\n<\/li>\n\n\n\n<li><strong>Effects<\/strong>:\n<ul class=\"wp-block-list\">\n<li>Lowers serum triglycerides by <strong>20\u201350%<\/strong> (at doses ~3\u20134 g\/day)<\/li>\n\n\n\n<li>Can slightly raise HDL<\/li>\n\n\n\n<li>May shift LDL toward less dense forms<\/li>\n<\/ul>\n<\/li>\n<\/ul>\n\n\n\n<hr class=\"wp-block-separator has-alpha-channel-opacity\"\/>\n\n\n\n<h3 class=\"wp-block-heading\">ADDITIONAL NOTES<\/h3>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Combination therapy<\/strong>:\n<ul class=\"wp-block-list\">\n<li>Certain agents (e.g., ezetimibe + statin, or bile acid sequestrant + statin) have <strong>additive LDL-lowering<\/strong> effects.<\/li>\n<\/ul>\n<\/li>\n\n\n\n<li><strong>Beyond Lipid Lowering<\/strong>:\n<ul class=\"wp-block-list\">\n<li>Many lipid-lowering drugs (especially statins) have <strong>pleiotropic effects<\/strong>:\n<ul class=\"wp-block-list\">\n<li><strong>Plaque stabilization<\/strong><\/li>\n\n\n\n<li><strong>Anti-inflammatory properties<\/strong><\/li>\n\n\n\n<li><strong>Improved endothelial function<\/strong><\/li>\n<\/ul>\n<\/li>\n<\/ul>\n<\/li>\n<\/ul>\n\n\n\n<h2 class=\"wp-block-heading\">OVERVIEW oF TREATMENT GOALS<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Lifestyle modifications<\/strong> (for all patients with elevated LDL cholesterol):\n<ul class=\"wp-block-list\">\n<li><strong>Regular aerobic exercise<\/strong><\/li>\n\n\n\n<li><strong>Prudent diet<\/strong> (low in saturated fat, high in fiber)<\/li>\n\n\n\n<li><strong>Weight loss<\/strong> in overweight individuals<\/li>\n<\/ul>\n<\/li>\n\n\n\n<li><strong>Pharmacologic therapy<\/strong> depends on:\n<ul class=\"wp-block-list\">\n<li><strong><a href=\"https:\/\/myendoconsult.com\/learn\/courses\/primary-prevention-of-ascvd\/\"  data-wpil-monitor-id=\"295\">Primary prevention<\/a><\/strong> (no coronary heart disease [CHD])<\/li>\n\n\n\n<li><strong>Secondary prevention<\/strong> (presence of CHD or CHD risk equivalent)<\/li>\n<\/ul>\n<\/li>\n<\/ul>\n\n\n\n<hr class=\"wp-block-separator has-alpha-channel-opacity\"\/>\n\n\n\n<h3 class=\"wp-block-heading\">PRIMARY PREVENTION<\/h3>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>When to Treat<\/strong>:\n<ul class=\"wp-block-list\">\n<li>If <strong>LDL<\/strong> remains high <strong>despite<\/strong> lifestyle measures<\/li>\n\n\n\n<li>If CHD <strong>risk assessment<\/strong> (e.g., Framingham) indicates pharmacologic treatment<\/li>\n<\/ul>\n<\/li>\n\n\n\n<li><strong>First-Line Therapy<\/strong>:\n<ul class=\"wp-block-list\">\n<li><strong>HMG-CoA reductase inhibitors (statins)<\/strong><\/li>\n\n\n\n<li>Statins lower CHD risk by <strong>20\u201330%<\/strong><\/li>\n<\/ul>\n<\/li>\n\n\n\n<li><strong>Typical Statin Doses<\/strong>:\n<ul class=\"wp-block-list\">\n<li><strong>Atorvastatin<\/strong> 10 mg<\/li>\n\n\n\n<li><strong>Lovastatin, Pravastatin, or Simvastatin<\/strong> 20 mg<\/li>\n<\/ul>\n<\/li>\n\n\n\n<li><strong>Expected Lipid Changes<\/strong>:\n<ul class=\"wp-block-list\">\n<li><strong>LDL<\/strong> \u2193 by <strong>30\u201360%<\/strong><\/li>\n\n\n\n<li>Some statins (e.g., <strong>atorvastatin<\/strong>, <strong>rosuvastatin<\/strong>) also lower <strong>triglycerides<\/strong><\/li>\n<\/ul>\n<\/li>\n\n\n\n<li><strong>Adverse Effects<\/strong>:\n<ul class=\"wp-block-list\">\n<li>Potential <strong>hepatic enzyme elevations<\/strong><\/li>\n\n\n\n<li>Rare <strong>diffuse myalgias<\/strong><\/li>\n\n\n\n<li><strong>Rhabdomyolysis<\/strong> (1 per 15 million prescriptions), more common if combined with:\n<ul class=\"wp-block-list\">\n<li><strong>Fibrates<\/strong> (notably <strong>gemfibrozil<\/strong> > fenofibrate)<\/li>\n\n\n\n<li><strong>Cyclosporine<\/strong><\/li>\n<\/ul>\n<\/li>\n<\/ul>\n<\/li>\n<\/ul>\n\n\n\n<hr class=\"wp-block-separator has-alpha-channel-opacity\"\/>\n\n\n\n<h3 class=\"wp-block-heading\">SECONDARY PREVENTION<\/h3>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Patient Population<\/strong>:\n<ul class=\"wp-block-list\">\n<li>Individuals with <strong>CHD<\/strong> or CHD equivalent (e.g., diabetes)<\/li>\n\n\n\n<li><strong>Risk<\/strong> of future myocardial infarction is <strong>20\u00d7<\/strong> higher in these patients<\/li>\n<\/ul>\n<\/li>\n\n\n\n<li><strong>Benefits of Cholesterol Lowering<\/strong> in CHD:\n<ul class=\"wp-block-list\">\n<li><strong>13\u201316%<\/strong> reduction in mortality<\/li>\n\n\n\n<li>Slows progression and <strong>may induce regression<\/strong> of coronary atherosclerosis<\/li>\n\n\n\n<li>Greatest benefit when <strong>LDL &lt;100 mg\/dL<\/strong><\/li>\n<\/ul>\n<\/li>\n\n\n\n<li><strong>Treatment Approach<\/strong>:\n<ul class=\"wp-block-list\">\n<li><strong>Statins<\/strong> (titrate every 6 weeks to achieve LDL &lt;100 mg\/dL)<\/li>\n\n\n\n<li>In <strong>acute MI<\/strong> setting: high-dose statin (e.g., atorvastatin 80 mg\/d) to target <strong>LDL &lt;70 mg\/dL<\/strong><\/li>\n\n\n\n<li>If <strong>LDL goal not met with statin alone<\/strong>:\n<ul class=\"wp-block-list\">\n<li>Add <strong>cholesterol absorption inhibitor<\/strong> (ezetimibe)<\/li>\n\n\n\n<li>Or add <strong>bile acid sequestrant<\/strong><\/li>\n<\/ul>\n<\/li>\n\n\n\n<li><strong>Statin intolerance<\/strong> (myopathy):\n<ul class=\"wp-block-list\">\n<li>Consider alternative agents or <strong>pravastatin<\/strong> (lower myopathy risk)<\/li>\n<\/ul>\n<\/li>\n<\/ul>\n<\/li>\n<\/ul>\n\n\n\n<hr class=\"wp-block-separator has-alpha-channel-opacity\"\/>\n\n\n\n<h3 class=\"wp-block-heading\">RAISING HIGH-DENSITY LIPOPROTEIN (HDL) CHOLESTEROL<\/h3>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Low HDL<\/strong> is common in patients with premature CHD<\/li>\n\n\n\n<li><strong>Lifestyle Measures<\/strong> to increase HDL:\n<ul class=\"wp-block-list\">\n<li><strong>Exercise<\/strong><\/li>\n\n\n\n<li><strong>Weight loss<\/strong> (if obese)<\/li>\n\n\n\n<li><strong>Smoking cessation<\/strong><\/li>\n<\/ul>\n<\/li>\n\n\n\n<li><strong>Medications<\/strong> that may help increase HDL by 15\u201330%:\n<ul class=\"wp-block-list\">\n<li><strong>Nicotinic acid<\/strong><\/li>\n\n\n\n<li><strong>Gemfibrozil<\/strong><\/li>\n\n\n\n<li><strong>Estrogen replacement therapy<\/strong> in postmenopausal women<\/li>\n<\/ul>\n<\/li>\n\n\n\n<li><strong>Drugs that lower HDL<\/strong> (e.g., androgens, benzodiazepines, \u03b2-blockers) should be discontinued if possible<\/li>\n<\/ul>\n\n\n\n<hr class=\"wp-block-separator has-alpha-channel-opacity\"\/>\n\n\n\n<h3 class=\"wp-block-heading\">HYPERTRIGLYCERIDEMIA<\/h3>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Rationale<\/strong>:\n<ul class=\"wp-block-list\">\n<li>Triglyceride-rich lipoproteins (VLDL, chylomicrons) also transport cholesterol<\/li>\n\n\n\n<li>Managing <a href=\"https:\/\/myendoconsult.com\/learn\/topics\/hypertriglyceridemia\/\"  data-wpil-monitor-id=\"294\">hypertriglyceridemia<\/a> helps correct hypercholesterolemia<\/li>\n<\/ul>\n<\/li>\n\n\n\n<li><strong>Combined High LDL + High Triglycerides<\/strong>:\n<ul class=\"wp-block-list\">\n<li><strong>Statins<\/strong> often first choice<\/li>\n<\/ul>\n<\/li>\n\n\n\n<li><strong>Triglycerides >1000 mg\/dL<\/strong>:\n<ul class=\"wp-block-list\">\n<li>Risk of <strong>chylomicronemia syndrome<\/strong> (pancreatitis, eruptive xanthomas, lipemia retinalis)<\/li>\n\n\n\n<li><strong>Immediate<\/strong> therapy (e.g., fibrates, nicotinic acid) to prevent pancreatitis<\/li>\n<\/ul>\n<\/li>\n<\/ul>\n\n\n\n<hr class=\"wp-block-separator has-alpha-channel-opacity\"\/>\n\n\n\n<h3 class=\"wp-block-heading\">MONITORING<\/h3>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Frequency<\/strong>:\n<ul class=\"wp-block-list\">\n<li><strong>Every 6\u20138 weeks<\/strong> until LDL goal is achieved<\/li>\n\n\n\n<li><strong>Every 6\u201312 months<\/strong> thereafter<\/li>\n<\/ul>\n<\/li>\n\n\n\n<li><strong>Liver Function Tests<\/strong>:\n<ul class=\"wp-block-list\">\n<li>Check at time of blood sampling with each dose change (especially for statins)<\/li>\n<\/ul>\n<\/li>\n<\/ul>\n\n\n\n<p><\/p>\n","protected":false},"excerpt":{"rendered":"<p>OVERVIEW OF LIPID-LOWERING AGENTS 1. CHOLESTEROL ABSORPTION INHIBITORS 2. HMG-CoA REDUCTASE INHIBITORS (STATINS) 3. BILE ACID SEQUESTRANTS 4. NICOTINIC ACID (NIACIN) 5. FIBRIC ACID DERIVATIVES 6. FISH OIL (OMEGA-3 FATTY ACIDS) ADDITIONAL NOTES OVERVIEW oF TREATMENT GOALS PRIMARY PREVENTION SECONDARY PREVENTION RAISING HIGH-DENSITY LIPOPROTEIN (HDL) CHOLESTEROL HYPERTRIGLYCERIDEMIA MONITORING<\/p>\n","protected":false},"featured_media":0,"template":"","oen_topic_chapter":[688],"class_list":["post-4422586","oen_topic","type-oen_topic","status-publish","hentry","oen_topic_chapter-lipid-metabolism","post-wrapper","thrv_wrapper"],"_links":{"self":[{"href":"https:\/\/myendoconsult.com\/learn\/wp-json\/wp\/v2\/oen_topic\/4422586","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/myendoconsult.com\/learn\/wp-json\/wp\/v2\/oen_topic"}],"about":[{"href":"https:\/\/myendoconsult.com\/learn\/wp-json\/wp\/v2\/types\/oen_topic"}],"version-history":[{"count":5,"href":"https:\/\/myendoconsult.com\/learn\/wp-json\/wp\/v2\/oen_topic\/4422586\/revisions"}],"predecessor-version":[{"id":4422593,"href":"https:\/\/myendoconsult.com\/learn\/wp-json\/wp\/v2\/oen_topic\/4422586\/revisions\/4422593"}],"wp:attachment":[{"href":"https:\/\/myendoconsult.com\/learn\/wp-json\/wp\/v2\/media?parent=4422586"}],"wp:term":[{"taxonomy":"oen_topic_chapter","embeddable":true,"href":"https:\/\/myendoconsult.com\/learn\/wp-json\/wp\/v2\/oen_topic_chapter?post=4422586"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}